Find policies, billing codes, payers, states, and providers
Surgical Dressings (Wound Care Supplies)
Customize your policy alerts
Sign up for Aetna Policy 0526 alerts
Get alerted when Policy 0526 changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity, limitations, and coverage criteria for surgical dressings and wound care supplies for Aetna members, including permitted frequencies, quantities, and product-specific guidance for home and provider-dispensed supplies.
No material clinical or coverage changes in this revision.
Coverage Criteria
inv-01: General medical necessity and supply quantity
Covered when ALL of the following are met
Suppliers expected to monitor actual utilization and adjust quantities
inv-02: Individual product coverage criteria
Product-specific coverage rules (each set applies when that product is used for indicated wound type/exudate level)
Not beneficial on dry wounds or wounds with eschar; usually not used with hydrogels
Contact layers are not intended to be changed with every dressing change
Use of both hydrogel filler and hydrogel cover on the same wound at the same time is of no proven benefit
inv-03: Compatibility and change-frequency guidance
Avoid combinations that necessitate frequent changes (e.g., specialty absorptive dressing over non-impregnated gauze)
inv-04: Experimental / investigational (examples)
The following are considered experimental/investigational (not covered) due to insufficient evidence
These items are considered experimental/investigational due to insufficient evidence
inv-05: General coverage (diagnosis and code contingent)
Covered when selection criteria are met for listed diagnoses and HCPCS codes
Selection criteria for specific codes/diagnoses must be documented in the medical record
inv-06: Evidence-summary coverage considerations
Summary of coverage-relevant clinical findings from cited evidence (useful for determining medical necessity or utilization management):
Consider sutures when minimizing dehiscence is a priority
Dressing choice may be based on cost and patient preference
Further high-quality studies are needed
Consider documenting rationale when using these products
Routine use of NPWT in this indication is not supported by the cited trial
Treat OxyBand as limited/preliminary evidence when considering coverage
Supports coverage when product labeling and clinical indication align
Under Aetna’s standard traditional plans (Managed Choice POS, PPO, and indemnity), surgical dressings are covered only when prescribed by a physician and supplied by a home care agency in conjunction with covered home health services or when dispensed and used by a participating health care provider in conjunction with treatment. Supplies that do not require a prescription, are available over-the-counter, or are provided to the member as take-home supplies are not covered under traditional plans; benefit plan descriptions should be checked for specific plan variations.
Certain items are explicitly identified as outside the surgical dressings benefit. Examples include elastic stockings, support hose, pressure garments and adhesion barriers (HCPCS C1765). The policy also lists specific HCPCS/CPT codes that are noted as not covered under the surgical dressings benefit (for example, A4216/A4217 among others); see the CPT/HCPCS code sections for the full enumerated lists and exceptions.
The policy explicitly calls out certain HCPCS codes and items as not covered under the surgical dressings benefit. Examples include bulk or large-volume sterile water/saline (e.g., A4217), skin sealants/protectants (e.g., A6250), wound cleansers (e.g., A6260), and other listed codes (see code tables). In addition, multiple ICD-10 diagnosis codes (such as pressure ulcer stage I–II and specified superficial injury codes) are listed as not covered for the indications shown in the CPB when billed under the surgical dressings benefit.
Evidence for the OxyBand oxygen-diffusion dressing is limited and preliminary. A small randomized study of donor-site dressings enrolled 20 patients with 17 completers and reported shorter mean time to healing and lower pain scores for OxyBand versus Xeroform; however, the trial size was small and the authors concluded the findings require validation in larger, well-designed studies before widespread adoption.
Chlorhexidine-impregnated dressings have evidence from randomized trials and meta-analyses showing reduced catheter colonization and CRBSI in some settings, but the Centers for Disease Control and Prevention recommends their use only when the product has an FDA-cleared label specifying an indication for reducing catheter-related bloodstream infection and when applied to short-term, non-tunneled central venous catheters in adults.
Surgical dressing kits that are standardized, non-individualized, or contain fixed quantities and materials not specifically prescribed for a member’s wounds are considered not medically necessary. When components are not each prescribed for the individual wounds of the member or the kit contains extra materials beyond the prescribed surgical dressings, the kit will be denied as not medically necessary.
Negative pressure dressings are considered not medically necessary for open fractures (see CPB 0334) because randomized evidence does not show benefit over standard dressings in this indication. The policy also lists specific dressings considered experimental/investigational (and therefore not covered), including ibuprofen foam dressings for painful venous leg ulcers and several other novel products.
Use of the HCPCS codes enumerated as ‘not covered under surgical dressings benefit’ or billing for indications specifically listed as not covered (for example, pressure ulcer stage I–II or unspecified codes and certain superficial injury/open fracture codes) will be considered not medically necessary and may be denied when submitted under the surgical dressings benefit. Providers should confirm the appropriate ICD-10 code and that the HCPCS code billed is applicable and allowed under the member’s benefit.
A large multicenter randomized trial (n=460) comparing negative pressure wound therapy versus standard dressings for severe open lower-limb fractures found no improvement in disability, deep infection rates, or quality of life at 12 months with NPWT. These findings do not support routine use of NPWT for this indication and inform the policy position that NPWT is not superior to standard dressing in severe open lower-limb fractures.
Coding and Billing Codes
| 16020 | Dressings and/or debridement of partial-thickness burns, initial or subsequent; small (less than 5% total body surface are). |
| 16025 | medium (eg, whole face or whole extremity, or 5 % to 10% total body surface area). |
| 16030 | large (eg, more than one extremity, or greater than 10% total body surface area). |
| 96574 | Debridement of premalignant hyperkeratotic lesion(s) (ie, targeted curettage, abrasion) followed with photodynamic therapy by external application of light to destroy premalignant lesions of the skin and adjacent mucosa with application and illumination/activation of photosensitizing drug(s) provided by a physician or other qualified health care. |
| 97597 | Debridement (eg, high pressure waterjet with/without suction, sharp selective debridement with scissors, scalpel and forceps), open wound, (eg, fibrin, devitalized epidermis and/or dermis, exudate, debris, biofilm), including topical application(s), wound assessment, use of a whirlpool, when performed and instruction(s) for ongoing care, per session total wound(s) surface area; first 20 sq cm or less. |
| 97598 | each additional 20 sq cm, or part thereof (list separatley in addition to code for primary procedure). |
| 97602 | Removal of devitalized tissue from wound(s), non-selective debridement, without anesthesia (eg, wet-to-moist dressings, enzymatic, abrasion), including topical application(s), wound assessment, and instruction(s) for ongoing care, per session. |
| A4216 | Sterile water, saline and/or dextrose, dilute flush, 10 ml [not covered under surgical dressings benefit] |
| A4450 | Tape, non-waterproof, per 18 sq. in. |
| A4452 | Tape, waterproof, per 18 sq. in. |
| A4217 | Sterile water/saline, 500 ml [not covered under surgical dressings benefit] |
| A4450 | Tape, non-waterproof, per 18 sq. in. |
| A4452 | Tape, waterproof, per 18 sq. in. |
| A4649 | Surgical supply; miscellaneous. |
| A6025 | Gel sheet for dermal or epidermal application (e.g., silicone, hydrogel, other), each |
| A6154 | Wound pouch, each |
| A6196-A6199 | Alginate or other fiber gelling dressing |
| A6200-A6205 | Composite dressing |
| A6206-A6208 | Contact layer |
| A6209-A6215 | Foam dressing [not covered for ibuprofen foam dressings for painful venous leg ulcers] |
| A6402-A6404 | Gauze, non-impregnated, sterile |
| A6441 | Padding bandage, nonelastic, nonwoven/nonknitted, width greater than or equal to 3 in. and less than 5 in., per yd. |
| A6442-A6447 | Conforming bandage, nonelastic |
| A6448-A6452 | Light, moderate, and high compression bandage, elastic |
| A6453-A6455 | Self-adherent bandage, elastic |
| A6456 | Zinc paste impregnated bandage, nonelastic, knitted/woven, width greater than or equal to 3 in., and less than 5 in., per yd. |
| A6460-A6461 | Synthetic resorbable wound dressing, sterile, pad without adhesive border, each dressing |
| C1765 | Adhesion barrier [not covered under surgical dressings benefit] |
| A4364 | Adhesive, liquid or equal, any type, per oz. [not covered as an alternative to sutures in wound closure] |
| A4550 | Surgical trays [not covered for provision or surgical dressings] |
| A6550 | Wound care set, for negative pressure wound therapy electrical pump, includes all supplies and accessories. |
| A9272 | Wound suction, disposable, includes dressing, all accessories and components, any type, each. |
| E2402 | Negative pressure wound therapy electrical pump, stationary or portable. |
| K0743 | Suction pump, home model, portable, for use on wounds. |
| K0744 | Absorptive wound dressing for use with suction pump, home model, portable, pad size 16 sq in or less. |
| K0745 | Absorptive wound dressing for use with suction pump, home model, portable, pad size more than 16 sq in but less than or equal to 48 sq in. |
| K0746 | Absorptive wound dressing for use with suction pump, home model, portable, pad size greater than 48 sq in. |
| A6010-A6011 | Collagen based wound filler. |
| A6021-A6024 | Collagen dressing. |
| A6457 | Tubular dressing with or without elastic, any width, per linear yard. |
| HCPCS Modifier A1-A9 | Modifiers indicating the number of wounds per dressing (A1 = Dressing for one wound ... A9 = Dressing for nine or more wounds). |
| L89.003-L89.004, L89.013-L89.014, ... | Pressure ulcer [stage III or IV] (multiple specific codes listed). |
| L97.100-L97.929 | Non-pressure chronic ulcer [stage III or IV]. |
| T20.20x+ - T25.799+ (various) | Burns and corrosion codes (second or third degree) for multiple body regions. |
| T81.83x+ | Persistent postprocedural fistula. |
| L08.9 | Local infection of the skin and subcutaneous tissue, unspecified (listed as ICD-10 not covered for CPB indications). |
| L89.000 - L89.002, L89.009 - L89.012, ... | Pressure ulcer codes for stage I, II or unspecified (listed as not covered for CPB indications). |
| Numerous S-, S7-, S8- ranges | Open fractures and superficial injuries codes (many listed as not covered for CPB indications). |
Provider Actions and Requirements
Surgical Dressing Kits
When surgical dressing kits are provided, they will be considered not medically necessary because kits are non‑individualized packaging with fixed quantities or include materials not specifically prescribed for the member's wounds. Surgical dressings must be tailored to the member's individual needs; kits/trays that contain repetitive quantities or extra materials that are not each prescribed should not be billed as medically necessary.
- Surgical dressing kits (standardized trays) are not medically necessary and may be denied.
Quantity Limits and Denials for Excess Supplies
Quantities of non‑reusable items that exceed stated limits will be denied as not medically necessary. Examples include gradient compression wraps (limited to one per 6 months per leg) and other single-use items where policy-specific limits apply. Suppliers should monitor actual patient use and document medical necessity for quantities beyond routine limits (e.g., >1 month supply or more frequent dressing changes).
- Gradient compression wrap: limited to one per 6 months per leg; quantities exceeding this will be denied.
- General rule: no more than a 1‑month supply of dressings is medically necessary at one time unless documentation supports greater quantity.
Billing Denials for Specific Codes and Diagnoses
Certain HCPCS codes and specific diagnoses may be denied when billed under the surgical dressings benefit. Verify that the code is covered for the intended indication and that selection criteria are met for covered ICD‑10 diagnoses. Billing for items that are explicitly listed as not covered may result in denial.
- Examples of HCPCS not covered under the surgical dressings benefit: A4364, A4550 (surgical trays), A6550, A9272, E2402, K0743–K0746 (home suction pumps and related pads) — confirm benefit alignment before billing.
- ICD‑10: pressure ulcers stage I–II or unspecified are not covered for the surgical dressings benefit; only stage III–IV and other specified covered codes apply when selection criteria are met.
Denial Risk When Evidence Is Low or Uncertain
Because high‑quality evidence is limited or very low for many dressing comparisons (including some specialty, antimicrobial, or novel dressings), coverage may be limited or denied when requested products lack clinical superiority for the proposed indication. Providers should choose dressings based on clinical need, cost, and patient preference when evidence does not demonstrate clear benefit.
- When evidence is very low or uncertain for a requested dressing compared with alternatives, denials are possible; document rationale for selecting a more costly or less well‑studied dressing.
Alignment with FDA‑Cleared Indication for Chlorhexidine‑Impregnated Dressings
Use of chlorhexidine‑impregnated dressings for short‑term, non‑tunneled central venous catheters in adults should align with FDA‑cleared labeling that specifies an indication for reducing catheter‑related bloodstream infection (CRBSI/CABSI). When claiming CRBSI/CABSI prevention, ensure the product's FDA clearance supports that indication.
- Align use with CDC recommendation and FDA‑cleared indication for short‑term, non‑tunneled CVCs in adults.
- If the product is not FDA‑cleared for CRBSI/CABSI reduction, document the clinical rationale and supporting evidence if used.
Documentation Supporting Medical Necessity for Quantities and Frequency
Documentation must support medical necessity for quantities or frequencies beyond standard limits (for example, more than a 1‑month supply, more frequent dressing changes than policy defaults, or billing multiple units of filler). Suppliers are expected to track actual use and adjust shipments accordingly.
- Document the current wound status, exudate level, frequency of required dressing changes, and why standard quantity limits are insufficient.
- Suppliers should have a mechanism to verify actual dressing use and adjust future provision.
Documentation of Diagnosis and Selection Criteria
Selection criteria and clinical diagnosis must be documented for covered indications. For example, ICD‑10 codes for pressure ulcers, burns, persistent postprocedural fistula, and stage III/IV chronic ulcers require supporting clinical information to meet selection criteria for coverage.
- Document the specific diagnosis (ICD‑10), wound stage (e.g., pressure ulcer stage III/IV), wound etiology, and clinical findings that meet the policy’s selection criteria.
- Selection criteria must be met and clearly recorded in the medical record for the listed ICD‑10 codes to be considered covered.
Documentation When Using Chlorhexidine‑Impregnated Dressings
When using chlorhexidine‑impregnated dressings for central venous catheters, document the indication, catheter type, and supporting evidence in the chart. The CDC recommends use for short‑term, non‑tunneled central venous catheters in adults when the dressing is FDA‑cleared for CRBSI/CABSI reduction.
- Document catheter type (short‑term, non‑tunneled CVC), indication for chlorhexidine‑impregnated dressing, and cite the FDA‑cleared labeling or supporting RCT/meta‑analysis evidence.
- If claiming CRBSI/CABSI prevention, include clinical rationale, dressing change frequency, and any relevant nursing care protocols.
Required Clinical Documentation
Required clinical documentation should include the clinical indication for the dressing, wound characteristics (size, depth, stage, amount of exudate), intended dressing change frequency, and whether the dressing type is tailored to the wound. For chlorhexidine dressings over CVCs, document catheter type and indication.
- Record wound measurements, wound stage (e.g., stage III/IV pressure ulcer), exudate level, presence of infection, and prior treatments tried.
- Specify the dressing type, number of units dispensed, planned frequency of changes, and justification for any deviation from standard policy limits.
Avoid Use of Secondary Dressings with Frequently‑Changed Primary Dressings
Avoid using secondary dressings that are designed for less frequent changes on top of primary dressings that require more frequent changes. For example, do not place composite, foam, hydrocolloid, or transparent film secondary dressings over primary dressings that need daily changes; such combinations are typically not medically necessary.
- Do not use secondary dressings (composite, foam, hydrocolloid, transparent film) when the underlying primary dressing requires more frequent than the secondary's intended change interval.
- Document rationale if such a combination is clinically required (e.g., initially highly exudative wounds), and re‑evaluate as wound status changes.
Dressing Selection Preference When Evidence Is Lacking
When evidence does not show one postoperative dressing to be superior, selection may be based on cost and patient preference. Providers should document the clinical rationale for dressing choice when no clear evidence favoring one product exists.
- Dressing selection preference: choose among clinically appropriate options based on cost, availability, and patient preference when high‑quality evidence of superiority is lacking.
- Document the shared decision‑making or cost rationale when selecting a particular dressing.
Clinical Background and Evidence
Surgical dressings include primary and secondary dressings and wound fillers used to protect wounds, absorb exudate, maintain a moist environment, and assist debridement. Product selection should be based on wound depth, exudate level, and intended dressing change frequency; inappropriate combinations (for example, hydrating and absorptive dressings applied simultaneously) are generally not beneficial. Dressings designed for less-frequent changes (e.g., composite, foam, hydrocolloid, transparent film) should not be paired with primary dressings that require frequent changes.
inv-06 (cross-reference): Evidence-summary coverage considerations
Summary of clinical findings and evidence context (background):
Evidence from systematic reviews and RCTs
Consider cost and patient preference in absence of clear benefit
Further high-quality studies needed
Clinical reviewers should not assume routine benefit in this indication
Treat as preliminary evidence for coverage decisions
Coverage appropriate when clinical indication and FDA-cleared labeling align
Definitions and Terms
Revision History
Scheduled next policy review date.
Policy last reviewed.
Policy effective date.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.